Background/Objectives: The standard of care for acute bacterial skin and skin structure infections (ABSSSIs) requiring intravenous (IV) antibiotics includes vancomycin, administered over several days, in a hospital or outpatient setting resulting in significant costs. Dalbavancin, a long-acting single-dose lipoglycopeptide IV therapy may offer a cost-effective option for adult patients with ABSSSIs in Canada. Methods: A cost-utility analysis (CUA) was performed to evaluate the potential benefits of dalbavancin compared to other IV antibiotics for the treatment of adult patients with ABSSSIs who require IV antibiotics but whose hospitalization, if necessary, is anticipated to be £ 72 hours. Results: This analysis utilized a decision-analytic model showing that dalbavancin was dominant against all IV antibiotic comparators when considering the healthcare system or societal perspective and was associated with lower costs and improved patient adherence. For the sub-population analysis against PWID (people who inject drugs) and the homeless, dalbavancin generated even greater cost savings. Conclusions: We report that dalbavancin when used to treat ABSSSI requiring IV antibiotics may offer cost savings for Canadian healthcare providers through reduced hospitalization time, lower administration and labor costs, minimized risk of healthcare-acquired infections (HAIs), improved patient compliance and optimized resource allocation particularly in patients at risk of non-compliance (First Nations, the homeless and PWID).